Loading…
Acrivon Therapeutics, Inc. is projected to decline to $1.64 by 2027, a -1% move from its current price of $1.66. ACRV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.59 | $1.66 | $1.73 | -0.05% |
| May 30 | $1.57 | $1.66 | $1.75 | -0.10% |
| May 31 | $1.55 | $1.66 | $1.77 | -0.16% |
| Jun 1 | $1.53 | $1.66 | $1.79 | -0.21% |
| Jun 2 | $1.52 | $1.66 | $1.81 | -0.26% |
| Jun 3 | $1.50 | $1.65 | $1.82 | -0.31% |
| Jun 4 | $1.49 | $1.65 | $1.84 | -0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.49 | $1.65 | $1.84 | -0.36% |
| Week 2 | $1.42 | $1.65 | $1.91 | -0.73% |
| Week 3 | $1.37 | $1.64 | $1.97 | -1.09% |
| Week 4 | $1.33 | $1.64 | $2.02 | -1.45% |
| Week 5 | $1.29 | $1.63 | $2.06 | -1.80% |
| Week 6 | $1.26 | $1.62 | $2.10 | -2.16% |
| Week 7 | $1.23 | $1.62 | $2.13 | -2.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates AP3, a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV is the ticker for Acrivon Therapeutics, Inc. The current price is $1.75. The market capitalization is $74.9M and the market rank is 4407. The forecast indicates an upward price trajectory over the coming years, with 2026 average around $1.75, rising to a 2030 average of $2.09 and a 2050 average of $10.07, with a 2050 maximum of $22.11.
Long-term upside is suggested by the projected max prices, with the 2031–2050 period showing substantial increases in average values and corresponding ROI figures.
A major floor 25.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 30.7% above — a clean break opens room to run.
A major ceiling 43.4% above — clearing it would confirm fresh momentum.
Key ACRV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACRV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.73 | Sell | $1.70 | Sell |
| MA 10 | $1.75 | Sell | $1.75 | Sell |
| MA 20 | $1.87 | Sell | $1.79 | Sell |
| MA 50 | $1.73 | Sell | $1.78 | Sell |
| MA 100 | $1.76 | Sell | $1.80 | Sell |
| MA 200 | $1.84 | Sell | $2.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.15 | Neutral |
| Stoch RSI (14) | 21.48 | Neutral |
| CCI (20) | -100.84 | Sell |
| Williams %R (14) | -86.05 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -16.16 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 13.95 | Buy |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 36.49 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 1.71 | Sell |
| ADX (14) | 15.03 | Neutral |
| ATR (14) | 0.07 | Info |
The near-term technical picture is NEUTRAL. The RSI(14) is 50, with a SMA50 of $1.73 and a SMA200 of $1.84. Key levels to watch are support at $1.60 and resistance at $2.17. The 30-day price range spans from $1.34 to $2.29, reflecting modest volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.29 | $1.66 | $2.32 | 0% | Neutral | |
| $1.25 | $1.64 | $2.32 | -1% | Neutral | |
| $1.17 | $1.60 | $2.38 | -3% | Neutral | |
| $1.18 | $1.67 | $2.58 | +1% | Neutral | |
| $1.24 | $1.83 | $2.91 | +10% | Neutral | |
| $1.60 | $2.42 | $3.95 | +46% | Bullish | |
| $1.64 | $2.54 | $4.26 | +53% | Bullish | |
| $1.52 | $2.43 | $4.16 | +46% | Bullish | |
| $1.55 | $2.53 | $4.43 | +52% | Bullish | |
| $1.48 | $2.49 | $4.43 | +50% | Bullish | |
| $1.89 | $3.53 | $6.82 | +113% | Bullish | |
| $3.61 | $8.01 | $17.29 | +383% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.29 | $1.66 | $1.96 | +0.00% |
| June 2026 | $1.37 | $1.63 | $1.99 | -1.87% |
| July 2026 | $1.32 | $1.58 | $1.97 | -2.81% |
| August 2026 | $1.35 | $1.64 | $2.07 | +3.40% |
| September 2026 | $1.37 | $1.67 | $2.13 | +2.03% |
| October 2026 | $1.33 | $1.63 | $2.11 | -2.20% |
| November 2026 | $1.35 | $1.67 | $2.17 | +2.06% |
| December 2026 | $1.42 | $1.77 | $2.32 | +5.96% |
Click any year to see its month-by-month ACRV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACRV price prediction for 2026 points to an average of $1.66 (low $1.29, high $2.32) — a potential gain of 0% on today's $1.66. A consolidation phase looks the most probable path here.
In 2027, ACRV is projected to trade between $1.25 and $2.32, averaging $1.64 — a potential decline of -1% from today's $1.66. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
Acrivon Therapeutics, Inc.'s 2028 outlook centres on $1.60, within a $1.17 to $2.38 range. That is -2% versus the projected 2027 average. That marks a -3% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, ACRV could reach as high as $2.58, with a base case around $1.67 and support toward $1.18 — roughly +1% from $1.66. Price action looks broadly range-bound.
Expect ACRV to range from $1.24 to $2.91 through 2030. The $1.83 average target implies a +10% move from current prices. That is up +9% on the projected 2029 average. A consolidation phase looks the most probable path here.
The ACRV price prediction for 2031 points to an average of $2.42 (low $1.60, high $3.95) — a potential gain of +46% on today's $1.66. Momentum favours further upside here.
In 2032, ACRV is projected to trade between $1.64 and $4.26, averaging $2.54 — a potential gain of +53% from today's $1.66. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Acrivon Therapeutics, Inc.'s 2033 outlook centres on $2.43, within a $1.52 to $4.16 range. That is -4% versus the projected 2032 average. That marks a +46% change versus current levels. Momentum favours further upside here.
By 2034, ACRV could reach as high as $4.43, with a base case around $2.53 and support toward $1.55 — roughly +52% from $1.66. Buyers look set to stay in control over this stretch.
Expect ACRV to range from $1.48 to $4.43 through 2035. The $2.49 average target implies a +50% move from current prices. That is -2% versus the projected 2034 average. Momentum favours further upside here.
The ACRV price prediction for 2040 points to an average of $3.53 (low $1.89, high $6.82) — a potential gain of +113% on today's $1.66. Buyers look set to stay in control over this stretch.
In 2050, ACRV is projected to trade between $3.61 and $17.29, averaging $8.01 — a potential gain of +383% from today's $1.66. That is up +127% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ACRV today (≈ 602.409639 ACRV) could be worth
$4,826.53
+$3,826.53 (+383%) by 2050 · US Dollar
Based on the average projected ACRV price of $8.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACRVwould be worth at today's price.
$1,000 invested in ACRV on May 27, 2025 (≈ 909.090889 ACRV) would be worth
$1,509.09
+$509.09 (+50.9%) today · 1.51× · US Dollar
Based on a ACRV entry price of $1.1 vs. today's $1.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.76 | $943.18 | -5.7% |
| 1 month ago | $1.88 | $882.98 | -11.7% |
| 3 months ago | $1.84 | $902.17 | -9.8% |
| 6 months ago | $2.36 | $703.39 | -29.7% |
| 1 year ago | $1.1 | $1,509.09 | +50.9% |
| All time (3.5y) ago | $16.64 | $99.76 | -90.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACRV forecast.
Our base-case forecast reaches $3.30 around 2040.
Implied market cap at $3.30: $141.25M
The multi-year forecast shows a gradual shift from neutral to bullish over time. By 2030, the average price is expected to be $2.09 with a maximum of $3.35 and a minimum of $1.41, delivering an expected ROI of 19.2%. The forecast strengthens into 2031–2035, where average prices rise toward $2.80–$2.95 and ROIs range from about 58% to 66% as sentiment turns bullish.
In 2040 the average is projected at $4.24 with a max of $8.30 and a notable jump in ROI to 142.2%. By 2050 the average is $10.07 with a max of $22.11 and a potential ROI of 475.3%, reinforcing a clear bullish trajectory for the long haul. These projections imply sustained upside through 2031–2050, balanced by near-term volatility and the usual uncertainties surrounding a clinical-stage healthcare company.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $1.41, an average of $2.09, and a max of $3.35, with a projected ROI of 19.2%.
The forecast calls for a neutral near term through 2028, with a bullish outlook from 2031 onward. Key numbers include 2030 average $2.09 and 2050 max $22.11, with ROI rising to 475.3%. These are estimates, not guarantees.
Yes. The 2030 forecast lists a max of $3.35, which indicates the price could exceed $3 within 2030.
The current price is $1.75 and the market capitalization is $74.9M, with a market rank of 4407.
The near-term view is neutral with RSI(14) at 50, SMA50 at $1.73, SMA200 at $1.84, support at $1.60, and resistance at $2.17. The 30-day range is $1.34 to $2.29 and annualized volatility is 80%.
Acrivon Therapeutics, Inc. Community Discussion
0Share your Acrivon Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.